# Optimizing Salvage ART: Real-World Outcomes of Doravirine Plus DTG or BIC in Heavily Treatment-Experienced Persons Living with HIV

**Authors:** Irina Ianache, Roxana Radoi, Gratiela Tardei, Mike Youle, Cristiana Oprea

PMC · DOI: 10.3390/microorganisms14020390 · Microorganisms · 2026-02-06

## TL;DR

This study examines the effectiveness of doravirine-based treatments in HIV patients with extensive treatment histories.

## Contribution

The study provides real-world evidence on the efficacy of doravirine combined with DTG or BIC in heavily treatment-experienced HIV patients.

## Key findings

- Viral suppression was achieved in 68.3% of patients at 6 months and 75.0% at 12 months.
- DOR-based regimens were effective in patients with extensive antiretroviral therapy histories.
- Parenterally acquired HIV was more common in younger patients with longer ART exposure.

## Abstract

Management of heavily treatment-experienced people living with HIV (HTE-PWH) remains challenging due to long antiretroviral therapy (ART) exposure and limited treatment options. We conducted an observational, real-world-data study on HTE-PWH in active care at the “Victor Babeș” Hospital, Bucharest, receiving doravirine (DOR)-based salvage regimens combined with dolutegravir (DTG) or bictegravir (BIC). Epidemiological, clinical, and laboratory variables were analyzed according to HIV acquisition mode and salvage regimen. Sixty-nine PWH were included; 57.9% male, with a median age of 36 years. Median ART duration before switch was 21.5 years. HIV was acquired parenterally in childhood (PM) in 64.7% cases. Salvage regimens included BIC/FTC/TAF + DOR (50.0%), 3TC/TDF/DOR + DTG (35.2%), and 3TC/DTG + DOR (14.7%). The median nadir CD4 count was 37 cells/µL, and the median viral load at diagnosis was 5.24 log10 copies/mL. Switching was performed for regimen simplification (n = 32) or non-adherence-related virological failure (n = 37). At switch, 53.6% had detectable viremia. Viral suppression was achieved in 68.3% at 6 months and 75.0% at 12 months. Individuals with PM infection were younger and had longer ART exposure than those with heterosexual acquisition. DOR-based salvage regimens combined with DTG or BIC were effective in adherent HTE-PWH, particularly those with extensive ART histories.

## Linked entities

- **Chemicals:** doravirine (PubChem CID 58460047), dolutegravir (PubChem CID 54726191), bictegravir (PubChem CID 90311989), 3TC (PubChem CID 60825), TDF (PubChem CID 6398764), FTC (PubChem CID 60877), TAF (PubChem CID 71492247)

## Full-text entities

- **Genes:** PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** Dyslipidemia (MESH:D050171), coronary heart disease (MESH:D003327), RNA-HIV (MESH:D012327), inflammation (MESH:D007249), injury to (MESH:D014947), anxiety (MESH:D001007), neuro-psychiatric disorders (MESH:D001523), neoplasia (MESH:D009369), diabetes (MESH:D003920), viremia (MESH:D014766), fatigue (MESH:D005221), injecting (MESH:C000719195), lipodystrophy (MESH:D008060), intellectual disability (MESH:D008607), discrimination (MESH:D010468), toxicities (MESH:D064420), PM infection (MESH:D007239), cardiovascular diseases (MESH:D002318), HTE (MESH:D016609), myopathy (MESH:D009135), depression (MESH:D003866), Infectious and Tropical Diseases (MESH:D003141), HIV (MESH:D015658), panic attacks (MESH:D016584)
- **Chemicals:** TDF (MESH:D000068698), fostemsavir (MESH:C576364), BIC (MESH:C000620396), 3TC (MESH:D019259), DTG (MESH:C562325), DOR (MESH:C000592662), ARV (-), lipids (MESH:D008055), ibalizumab (MESH:C481504)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943049/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943049/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943049/full.md

---
Source: https://tomesphere.com/paper/PMC12943049